Pharma

CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Pharmaceutical, Health, CNS, DPP, Peptide, Patient, MOVE, Investigational New Drug, Human, Diabetes, Bangladesh Technical Education Board, Pharma, Inflammation, Energy, Diet, Safety, Treatment, IND, Cardiovascular disease, Division, Wellness, Harvard Medical School, Brigham, PYY, Overweight, Society, Physician, Obesity medicine, Adipose tissue, Medicine, FACP, DSM-IV codes, SAB, Pharmacokinetics, Defense, Peptide YY, Identification, Weill Cornell Medicine, Research, Nutritional science, The New York Times, Metabolism, DASH, NIH, Weight loss, Pharmaceutical industry, Soft drink, Dietary supplement, Obesity

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.

Key Points: 
  • CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.
  • The members of CinFina’s SAB include renowned metabolic and obesity academic researchers and expert clinicians.
  • Louis Aronne, M.D., FACP is a professor of metabolic research at Weill-Cornell Medical College, and director of the Center for Weight Management and Metabolic Clinical Research.
  • His research activities focus on understanding the mechanisms responsible for metabolic abnormalities associated with obesity and the therapeutic effects of weight loss.

Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer

Retrieved on: 
Monday, December 11, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Other Health, Safety, Rash, Liver, Patient, Pulmonary hypertension, FDA, Orthostatic hypertension, Corsair, Blood, Pain, PAH, Skin, Physician, Quality of life, Pharma, Pharmaceutical industry

Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the appointment of George W. Mahaffey as Chief Executive Officer.

Key Points: 
  • Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the appointment of George W. Mahaffey as Chief Executive Officer.
  • Mr. Mahaffey brings more than 35 years of pharmaceutical, biotech, device, and diagnostics experience, including having launched Ventavis®, the first FDA-approved inhaled prostacyclin product indicated for pulmonary arterial hypertension (PAH).
  • The Corsair transdermal patch is intended to provide continuous and consistent blood levels of the prostacyclin drug treprostinil comparable to an infusion pump.
  • PAH patients need new options for the delivery of this foundational drug class,” said Mr. Mahaffey.

Camena Bioscience Appoints Dr Nicola Thompson as Chair of the Board

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Environment, Health, Genetics, Green Technology, Acquisition, Cell biology, DNA, Therapy, Gene, Chair, Chairperson, Astellas Pharma, University College London, GSK, Roche, Growth, Doctor of Philosophy, Pharma, Pharmaceutical industry, Amphisbaena, Camena

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Key Points: 
  • Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
  • Dr Steve Harvey, CEO, Camena Bioscience commented: "Nicola is a successful CEO and Chair and a fantastic addition to the Board.
  • Camena Bioscience enables researchers to ‘write’ DNA with the same confidence and ease with which we can ‘read’ DNA.
  • Dr Nicola Thompson, Chair of the Board, Camena Bioscience, added: “I am delighted to join the Company as its Chair at this pivotal stage of growth.

Horus Pharma Is Strengthening Its International Expansion in Support of Its Growth

Retrieved on: 
Tuesday, December 5, 2023
Health, Other Health, Other Science, Research, Science, Optical, Biotechnology, Corporation, Ophthalmology, Retina, SME, Marketing, Moritz Moszkowski, Growth, Pharma, Glaucoma, Economic development, Pharmaceutical industry, Fine chemical

“We have made international expansion a key part of our growth since 2015.

Key Points: 
  • “We have made international expansion a key part of our growth since 2015.
  • Our international network constitutes a unique platform for marketing products and supporting the development of new treatments specific to local needs,” said Claude Claret, co-founder and CEO of Horus Pharma.
  • Horus Pharma’s portfolio features 60 innovative ophthalmology products and solutions, including cornea, eyelid, glaucoma and retina treatments, along with food supplements.
  • Horus Pharma has been selected to join the ETIncelles programme, which features 100 small and medium-sized enterprises (SMEs) with strong economic development potential.

Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers

Retrieved on: 
Monday, December 4, 2023
FDA, Health, Science, Pharmaceutical, Research, CQA, NYSE, Food, Inhaler, ATR, Multimedia, AptarGroup, Pharmaceutical industry, Pharma

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).
  • View the full release here: https://www.businesswire.com/news/home/20231204794277/en/
    Moreover, Aptar’s study will help to define the potential target product profile of low-GWP propellant MDIs to achieve comparability in critical quality attributes (CQAs) to existing MDIs.
  • Additional capabilities Aptar can provide include pilot manufacturing / process, analytical methods offering alternative pathways to clinical trials, formulation development, metering valve technology and more.
  • Moreover, the study is expected to support the ongoing FDA efforts to provide guidance on the regulatory framework with respect to the evaluation and approval of low-GWP propellant MDIs.

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer, Trichloroethylene, Acquisition, Innovation, Ingelheim am Rhein, Potyvirus, Boehringer Ingelheim, Tissue, Cancer, Innovation Unit, Patient, Bi-specific T-cell engager, Bacteria, Immunotherapy, CHF, Pharma, Fine chemical, Vaccine, Allschwil

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.

Key Points: 
  • Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.
  • T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
  • “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs.
  • Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches.

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

Retrieved on: 
Tuesday, November 21, 2023
Technology, Health, Cannabis, Women, Seniors, Pharmaceutical, Mental Health, Natural Resources, Artificial Intelligence, Consumer, Clinical Trials, NYSE, Risk, Clinical trial, Patient, IGC, Data analysis, Algorithm, Alzheimer's disease, Agitation, Dementia, LMP, University, Diagnosis, AI, Pharma, Drug development, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” "IGC" or the "Company") (NYSE American: IGC) today announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” "IGC" or the "Company") (NYSE American: IGC) today announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes.
  • IGC Pharma will be focused on advancing various AI initiatives including:
    Streamlining clinical trial efficiency: IGC Pharma’s leading drug asset, IGC-AD1, is currently in Phase 2 clinical trials for the treatment of agitation related to symptoms of Alzheimer’s disease, with four additional assets progressing towards clinical trials.
  • The Company believes that the integration of AI algorithms into clinical trials can significantly enhance trial efficiency including progress, cost reduction, and data analysis.
  • Enhancing early detection methods for Alzheimer’s disease: Early detection and diagnosis of Alzheimer’s disease is a key factor in effective treatment.

Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing

Retrieved on: 
Thursday, November 16, 2023
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Syringe, Glass, Safety, NYSE, Stevanato Group, Multimedia, Combi, Quality control, Endeavor Business Media, Engineering, Pharma, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20231116606597/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231116606597/en/
    Stevanato Group's Mavis™ Combi machine for visual inspection.
  • The Mavis™ Combi visual inspection line is a cutting-edge solution designed to provide advanced performance, flexibility, and speed to enhance visual inspection of primary packaging and the drugs within it.
  • The Mavis™ Combi is part of Stevanato Group's Mavis™ platform, which also includes equipment for visual inspection of syringes.
  • “It's a privilege to be acknowledged for the innovation behind the Mavis™ Combi visual inspection line,” said Paolo Superchi, Vice President of Engineering Operations at Stevanato Group.

3-Hour Root Cause Analysis, Corrective and Preventive Actions (CAPA) and Effectiveness Checks Virtual Seminar - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Health, General Health, Root cause analysis, Cosmetics, Quality, Organization, Consent decree, CAPA, Pareto analysis, Diagram, Knowledge, Animal Health, Risk management, Industrial design, Plasma, Blood, Pharma

The "3-Hour Virtual Seminar on Root Cause Analysis, CAPA and Effectiveness Checks" webinar has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "3-Hour Virtual Seminar on Root Cause Analysis, CAPA and Effectiveness Checks" webinar has been added to ResearchAndMarkets.com's offering.
  • This comprehensive course offers essential knowledge and practical skills in root cause analysis, corrective and preventive actions (CAPA), and conducting effectiveness checks.
  • Participants will learn systematic approaches to identify root causes, develop effective CAPA plans, and assess the success of implemented solutions.
  • Participants will learn to differentiate between corrective and preventive actions and develop robust CAPA plans to prevent recurring issues.

One Day Online Course: A Different Approach to Successful Clinical Research Projects - Unlock Success in Clinical Research with Innovative Project Strategies

Retrieved on: 
Monday, December 18, 2023
Constraint, Agile, Risk management, Agile management, ChromeOS, Theory, Complexity, Nursing, Management, Pharma

DUBLIN, Dec. 18, 2023 /PRNewswire/ -- The "Clinical Research - A Different Approach to Successful Project Delivery Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 18, 2023 /PRNewswire/ -- The "Clinical Research - A Different Approach to Successful Project Delivery Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • This course offers invaluable techniques to enhance the success of your clinical research project.
  • In the ever-evolving landscape of project management, this workshop encourages a fresh perspective on clinical research projects.
  • While concepts like System Thinking, the Theory of Constraints, and Agile Project Management aren't entirely new, they are often underutilized in the highly regulated realm of clinical research.